Infectious Diseases
- Ref-No. Technology
-
01-01030
Rapid quantitation of virus-neutralizing antibodies in biosamples - a novel BSL1 approach based on virus-like particles (VLPs)
-
02-00303
Novel Myxopyronin Analogues and Myxopyronin Genecluster for Mutasynthesis
-
02-00311
Cystobactamids – novel antibacterials against gram-negative pathogens
-
02-00324
Innovative DOTA-Linkers for Bacterial Targeting
-
02-00337
Novel Labyrinthopeptins as anti-viral agents
-
02-00351
Increased Availability and Efficacy of Aminoglycosides
-
02-00354
Highly active Chlorotonil A Derivatives for the treatment of Malaria
-
02-00372
Oral Antimotilin-Based Inhibitors for Treating Helicobacter pylori Infections
-
02-00373
First-in-Class S. aureus α-Hemolysin Inhibitors for Lung and Skin Infections
-
02-00374
Phytosphingosine Derivatives as Adjuvants in Immune Stimulation
-
02-00375
CRISPRdetect – multiplexed RNA detection with reprogrammed tracrRNAs
-
02-00376
Overcoming resistance - Innovative broad-spectrum inhibitors of Metallo- β-lactamases
-
02-00378
Best-In-Class P. aeruginosa LasB virulence factor Inhibitors
-
02-00387
Best-in-class Darobactin derivate against Gram-negative Bacteria
-
02-00396
Novel Lectin-Targeting therapeutics and diagnostics for Pseudomonas aeruginosa infections
-
02-00397
Novel vaccine vector platform for safe and effective immunization using a replication-deficient murine cytomegalovirus (MCMV)
-
02-00402
Novel inhibitors of Cytomegalovirus
-
02-00404
Inhibitors of Energy Coupling Factor (ECF) Transporters Against Gram-Positive Pathogens
-
02-00413
Rapid Detection of Shiga toxin producing E.coli (STEC)
-
02-00423
DeColi: Gut Decolonization of Multi-Resistant Escherichia coli
-
02-00432
Novel ASO-Based mRNA Silencing Technology for Phage-Host Interaction Research
-
10-00087
Jagaricin – a novel antifungal natural compound
-
10-00128
Functionalized Nanoparticles for Viral Clearance
-
14-00098
Targeting host lipid homeostasis to augment anti-mycobacterial treatment
-
14-00128
Blood-based tuberculosis precision medicine: transcriptomic model shortens therapy duration
-
14-00169
Blood-based tuberculosis precision medicine: transcriptomic model predicts treatment response
-
14-00176
Efficient, adjuvant-free mucosal vaccination via IgA feedback loop
-
15-00461b
Novel treatment for sepsis in newborns
-
18-00052
Broadly neutralizing antibodies against hepatitis E virus (HEV)
- 22-00020 Bispecific antibodies for cell-type-specific TNF inhibition
-
32-00083
Immunosuppressant resistance in anti-viral T cell products
-
32-00178
Broad-spectrum antiviral compounds against known and emerging viruses
-
32-00187
HSV signature antibodies predict the development of anti-NMDA receptor encephalitis
-
33-00002
Rapid, simultaneous and non-destructive blood diagnostics using a multi-omics NMR platform
-
33-00015
The Prognostic Umbilical Swab: A Rapid Molecular Risk Stratification Tool for Neonatal Sepsis and Brain Injury
-
43-00016
SARSeq: Multiplexed, parallel detection of SARS-CoV2 variants and other viruses in high-throughput
-
43-00016
Two-Dimensional Redundant Dual Barcoding for Ultra-High-Throughput, Error-Resilient Nucleic Acid Analysis
-
44-00013
Keratinophile photosensitizers for safe and rapid treatment of onychomycosis
